Glenn Archibald, MD
Psychiatry · Huntsville, ALNPI 1316947450
Payments from drug & device makers
Across 1,141 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$4K
- Alkermes, Inc.$3K
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Supernus Pharmaceuticals, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$2K
- plus $10K from 28 others
What the payments were for
- Food & beverage$23,16898%
- Education$4002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$2,163
- ARISTADA$1,425
- REXULTI$366
- ARISTADA INITIO$356
- INVEGA SUSTENNA$279
- NEUROSTAR TMS THERAPY SYSTEM$257
- ABILIFY MAINTENA$241
- QELBREE$201
- Jornay PM 20mg capsules (Bottle of 100)$195
- NUEDEXTA$125
- Fanapt$125
- Azstarys$122
- Dayvigo$121
- CAPLYTA$118
- COBENFY$118
- Auvelity$117
How this compares
$23,568 in reported general payments places this provider in the 90th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 181 | $278,179 |
| VraylarCariprazine Hcl | 160 | $271,408 |
| AustedoDeutetrabenazine | 34 | $198,056 |
| CaplytaLumateperone Tosylate | 76 | $131,912 |
| Austedo XrDeutetrabenazine | 12 | $130,009 |
| IngrezzaValbenazine Tosylate | 13 | $108,778 |
| TrintellixVortioxetine Hydrobromide | 183 | $99,742 |
| AplenzinBupropion Hbr | 12 | $99,138 |
| Wellbutrin XlBupropion Hcl | 14 | $53,015 |
| Invega SustennaPaliperidone Palmitate | 14 | $50,121 |
| Aripiprazole | 369 | $45,797 |
| FanaptIloperidone | 12 | $44,524 |
| Abilify MaintenaAripiprazole | 13 | $35,969 |
| VyvanseLisdexamfetamine Dimesylate | 88 | $34,701 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $22,700 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $1,610 | $328,06546 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $3,997 | $314,148194 claims |
| AbbVieVraylar | $2,050 | $271,408160 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $1,180 | $134,443271 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,985 | $131,91276 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $139 | $108,77813 claims |
| Bausch Health US, LLCAplenzin | $729 | $99,13812 claims |
| Johnson & JohnsonInvega Sustenna | $1,159 | $50,12114 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,508 | $44,52412 claims |
| Alkermes, Inc.Lybalvi | $2,519 | $22,70014 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $1,869 | $10,69415 claims |
| MerckBelsomra | $36 | $9,55416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 400 psychiatry providers in Alabama.
Other psychiatry in Huntsville
- Scariya KumaramangalamHuntsville$440K
- Sofia AeschlimannHuntsville$18K
- Heath PenlandHuntsville$11K
- Quratulain AghaHuntsville$10K
- Matthew MacalusoBirmingham$2.8M
- Richard SheltonBirmingham$2.4M
- Michael FalolaTrussville$2.2M
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.